Therapeutic effects of mesenchymal stem cell-derived extracellular vesicles from different tissue sources on diminished ovarian reserve and the related mechanisms.
Li J., Gu M., Wang Y., Qi Y., Xie W., Zhang Y.
Animal Study, published in J Nanobiotechnology (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Nanobiotechnology (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42057118
- PMCID
- PMC13274086
- DOI
- 10.1186/s12951-026-04403-4
Abstract (original English)
Background Patients with diminished ovarian reserve (DOR) significantly reduced success rates in assisted reproduction, making DOR a major clinical challenge in assisted reproductive technologies. Recent studies have indicated that extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) hold promise for improving ovarian function, yet the impact of tissue origin on EVs function remains unclear. Adipose tissue and the umbilical cord are common and easily accessible sources of MSCs. This study aimed to compare the therapeutic effects of adipose-derived MSC- EVs (A-EVs) and umbilical cord MSC- EVs (U-EVs) in a cyclophosphamide-induced DOR mouse model, investigate their underlying mechanisms and provide experimental evidence for selecting the most promising EVs source for clinical application. Results Proteomic analysis revealed differences protein composition between U-EVs and A-EVs. Both A-EVs and U-EVs significantly increased serum AMH levels and improved fertility, whereas U-EVs produced more sustained reproductive benefits. Single-cell RNA sequencing and in vitro functional validation demonstrated that EV treatment reduced granulosa-cell apoptosis, oxidative stress, DNA-damage responses, and senescence signatures, with U-EVs exerting broader regulatory effects. Conclusions In conclusion, both A-EVs and U-EVs improved ovarian function in DOR mice; however, U-EVs
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.